Death Grip Syndrome may sound alarming, Dr Cunningham explains, but it doesn’t do any physical damage to the penis in the ...

Some credit sex columnist Dan Savage with coining the term back in the early 2000s, but it’s also popped up in various Reddit threads ... to men’s health website Hims and medical adviser ...

Allen Lutz, an analyst from Bank of America Securities, maintained the Buy rating on Hims & Hers Health (HIMS – Research Report). The associated price target remains the same with $25.00.

Shares of Hims & Hers (NYSE:HIMS) fell 14% Wednesday following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer considered to be in short supply in the U.S. Certain doses of ...

Hims & Hers Health Inc. said an analysis of more than 10,000 patients taking a copycat version of Novo Nordisk A/S’s Ozempic and Wegovy showed the shot was a safe and effective way to shed pounds.

Investors with a lot of money to spend have taken a bearish stance on Hims & Hers Health (NYSE:HIMS). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Hims & Hers shares gained Monday after the Food and Drug Administration said compounding pharmacies could continue to produce copycat weight-loss drugs while it reconsiders whether there is a ...

Hims & Hers Health will join the S&P SmallCap 600 prior to the opening of trading on Wednesday. Hims & Hers will replace Vector Group, which is being acquired by JT Group. Hims & Hers Health Inc ...

Hims & Hers Health (HIMS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Cherny from Leerink Partners reiterated a Hold rating on ...